Demand for tuberculosis therapeutics is predicted to surpass US$846 million by 2015. Incidences of TB-HIV co-infections, the appearance of MDR- and XDR- strains of tuberculosis, and high rates of infection in developing area such as Africa and Asia, where the low rates of detection creating major difficulties in extinguishing the infection, all suggest a huge potential requirement for tuberculosis diagnosis and therapy. These circumstances reflect an exceptional market potential for existing suppliers and new entrants.
While modern medicine has rendered this highly contagious, and life-threatening disease curable, and treatable, the disease continues to challenge the medical community even to the present day. As the bacterium causing TB continues to evolve, mutate, and develop resistance against modern drugs, there exists an urgent and dire need to develop newer next generation drugs to fight the disease. The growing prevalence of XDR (extensively drug resistant) TB and MDR (multi-drug resistant) TB strains has created the need for newer diagnostics tools, and drugs to manage and control tuberculosis. R&D in this area confronts its toughest challenge ever, with global investments, and R& D funding on total TB research still continuing to fall short of requirements. The uncertainties over the level of the US government's contribution towards the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) has also taken its toll on research funding, leading to funding deficits. This shortfall in funds has knifed the availability of finances in high-burden regions, such as the Sub-Saharan region.
According to Global Industry Analysts, Controlling tuberculosis and preventing the progress of MDR- and XDR-TB strains will need more effective drugs and regimens. Several programs are underway to improve existing therapies and make drugs more accessible to patients. Market participants are boosting their TB related R&D spending to quickly move up novel candidates into proprietary technologies and innovative solutions that will drive both growth and profitability. Tuberculosis (TB) Therapeutics, is expected to exceed U$846 million by 2015. The hitherto witnessed complacency among pharma majors over the importance of new TB drug research and development is finally beginning to ease, thanks to the high voltage campaign undertaken by the Global Alliance for TB Drug Development to break the two popular myths that are prevalent in the industry. The misconception that TB is not an unmet medical need is rapidly melting against the heat generated by the brisk rise in the number of mutant, antibiotic resistant TB infections. The erroneously undervalued TB drugs/therapeutic market is now getting a new statistical makeover with the market's potential being more accurately quantified in conjunction with the rising TB incidence in developing countries, and the parallel rise in AIDS/HIV infections, which make TB control, management, and cure, a more complex, tough, expensive and daunting task.
Key players in the marketplace include AstraZeneca, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline Plc., Lupin Limited, Mylan Inc, Novartis AG, Ranbaxy Laboratories Limited, Rusan Pharma Ltd., Rx for Africa Inc., Sanofi-Aventis SA, Summit Plc, Tibotec BVBA, Otsuka Pharmaceutical Co. Ltd., Sequella Inc., Global Alliance for TB Drug Development, and Institute Of Microbiology, Chinese Academy Of Sciences, among others.
The report titled Tuberculosis Therapeutics: A Global Market Report by Global Industry Analysts, provides a comprehensive review of industry overview, product overview, product introductions/innovations, profiles of major players, and recent industry activity. The report analyzes market data and provides analytics in value sales for global market. Global Industry Analysts©.
Click for Report details:Tuberculosis Therapeutics: A Global Market Report